The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

Zucara Therapeutics Inc., a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent ...

Island Pharmaeuticals, Dimerix and Tryptamine Therapeutics are among ASX health stocks reporting quarterly results this week.

Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy ...

Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF) and ...

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces promising interim results ...